Last reviewed · How we verify
AMG 423
At a glance
| Generic name | AMG 423 |
|---|---|
| Sponsor | Cytokinetics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults (PHASE1)
- Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction (PHASE3)
- COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (PHASE2)
- Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency (PHASE1)
- Omecamtiv Mecarbil Post-trial Access Study (PHASE3)
- Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients (PHASE2)
- Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults (PHASE1)
- Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |